Evidence map›Paper›PMID 39797985›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Tocilizumab alleviated lipopolysaccharide-induced acute lung injury by improving PI3K/AKT pathway.

Junting Weng, Shuoyun Weng, Jitao Xu, Danjuan Liu, Rongjie Guo, Bingbing Shi, Min Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. No evidence for paradoxical effects of tocilizumab in rodents.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junting Weng *Department of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China.
Shuoyun Weng *Wenzhou Medical University School of Optometry and Ophthalmology, Wenzhou, 325035, China.
Jitao Xu *Department of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China.
Danjuan LiuDepartment of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China.
Rongjie GuoDepartment of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China.
Bingbing ShiDepartment of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China.
Min ChenDepartment of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China. ptfsyy65581@163.com.

Funding

the Fujian Provincial Health Technology Project 2023CXA055the Natural Science Foundation of Fujian Province 2024J011453the Natural Science Foundation of Fujian Province 2024J011456
6 · The paper itself

Abstract

Acute lung injury (ALI) is a severe inflammatory condition of the respiratory system, associated with high morbidity and mortality. This study investigates the therapeutic potential of tocilizumab (TZ), an IL-6 receptor inhibitor, in mitigating lipopolysaccharide (LPS)-induced ALI by modulating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. An ALI model was established using LPS induction. Lung damage was assessed by hematoxylin-eosin (H&E) staining, alongside measurements of respiratory function, including PaO

Indexed as

Acute Lung InjuryAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktAnimalsApoptosisCytokinesDisease Models, AnimalLipopolysaccharidesLungMaleMiceSignal TransductionAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsCytokinesLipopolysaccharidesPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-akttocilizumabAcute lung injuryApoptosisInflammationOxidative stressPI3K/AKTRespiratory functionTocilizumab

Identifiers

PMID39797985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.